SEC Form 4 · accession 0000899243-18-029157
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory L. Verdine
Director
Period of report
Nov 14, 2018
Accepted (ET)
Nov 16, 2018 · 5:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Nov 14, 2018 | S | 10,700 | $38.59 | D | 64,339 | D | |
| Ordinary SharesF2 | Nov 14, 2018 | S | 4,300 | $39.52 | D | 60,039 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $38.15 to $39.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F2The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $39.33 to $39.53 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price..